CORRECTING AND REPLACING — PDS Biotech Announces Release of Interim Data for PDS0101 in NCI-Led Phase 2 Clinical Study in Oral Presentation at ASCO 2021 Annual Meeting

NEXT STORY
Pyxis Oncology Strengthens Leadership Team with Executive and Scientific Advisory Board Appointments
PREV STORY
The Psyence Group Announces its Formal Entry into Jamaica with the Incorporation of its Wholly Owned Subsidiary, Psyence Jamaica Limited
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Helsinn Group and MEI Pharma Announce that Pracinostat has Received Orphan Drug Designation from the European Medicines Agency for the Treatment of acute myeloid leukemia (AML)

Helsinn Group and MEI Pharma Announce that Pracinostat has Received Orphan Drug Designation from ...

author_avatar
NASDAQ Market News

LivaNova to Webcast Presentations From Company’s Investor and Analyst Meeting

LONDON, Nov. 23, 2015 (GLOBE NEWSWIRE) -- LivaNova PLC (NASDAQ:LIVN) (LSE:LIVN) ("LivaNova" or the ...

author_avatar
NASDAQ Market News

Gritstone Announces First Patient Enrolled for Phase 2/3 Trial Evaluating Individualized Neoantigen Vaccine GRANITE for First Line (1L) Maintenance Treatment of Metastatic, Microsatellite-Stable Colorectal Cancer (MSS-CRC)

author_avatar
NASDAQ Market News